- 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose -- 6 patients attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -

MONROVIA, Calif. , June 8, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Raphael Clynes

MONROVIA, Calif. , May 30, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,

MONROVIA, Calif. , May 11, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced today that XmAb®5871 has been granted

-- Phase 1 Data from Subcutaneous Administration Trial of XmAb®5871 Support Biweekly Dosing ---- Management to Host Conference Call Today at 4:30 p.m. ET --

MONROVIA, Calif. , May 2, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter 2017

MONROVIA, Calif. , April 26, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,

MONROVIA, Calif. , April 17, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman , Ph.D., chief executive officer of Neurocrine

MONROVIA, Calif. , March 15, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,

MONROVIA, Calif. , March 6, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter , Ph.D., will not stand for reelection to the